-The Telegraph Centre’s vaccine policy advisers earlier this week approved release of intranasal vaccine into the private market New Delhi: Indian vaccine maker Bharat Biotech announced on Tuesday that its intranasal Covid-19 vaccine, approved by the Centre as a booster dose, would be available at private hospitals for Rs 800 plus additional taxes and service charges per dose. People 18 years or older who have taken two doses of Covaxin, Covishield or any...

-Hindustan Times On November 15, Boston-based health news website Stat News cited official documents that purported to detail a series of problems in how Bharat Biotech’s coronavirus vaccine, funded partly by the government, was approved. The Union government and vaccine maker Bharat Biotech on Thursday refuted a report that alleged rules and protocols were bent during the approval process for Covaxin, but the clarifications served to further add to the questions that...

-IndiaToday.in Private hospitals will now be able to buy a single dose of Covid-19 vaccines Covishield and Covaxin at Rs 225. A single dose of the Serum Institute of India's Covishield and Bharat Biotech's Covaxin will now cost private hospitals Rs 225. Private hospitals will charge Rs 150 for administering the dose. Adar Poonawalla, CEO of SII, said in a tweet on Saturday that the vaccine maker has decided to slash the prices...

Scientific knowledge has immensely helped in combating the dreadful coronavirus and its spread. Within a record short period of time, scientists (including virologists, epidemiologists, biostatisticians, etc.) and their research outputs helped the commoners to learn more about the SARS-CoV-2 and how it spreads from one individual to the next one. Common people have now come to know how simple techniques and behavioural change like the wearing of N95 masks, maintaining...

-The Hindu Top COVID-19 vaccination official responded to query on mismatch with Health Ministry’s number of 135 crore doses. A May 13 estimate, by one of India’s top officials overseeing the pandemic response, that India would have 216 crore doses of vaccines from August-December was based on an “optimistic, aspirational assessment” and based on what vaccine manufacturers had conveyed to the government. VK Paul, Chairman, National Empowered Group on Vaccine at a press briefing...